Traduction de «with health » (Néerlandais → Français) :

TERMINOLOGIE

AERRPS - acute encephalitis with refractory repetitive partial seizures
syndrome épileptique par infection fébrile

CMDH - congenital muscular dystrophy with hyperlaxity
dystrophie musculaire congénitale avec hyperlaxité

periodiek onderzoek (jaarlijks)(lichamelijk) | 'health check-up' NNO
Bilan de santé SAI Examen périodique (annuel) (physique)

TRADUCTIONS EN CONTEXTE

Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)
Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office DGO - SCM guidance committee (with APB and OPHACO) e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees ICVV – CICSA Influenza (in cooperation with external partners) Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Inter DG drugs (with FPS Public Health) Mdeon board of management Potassium iodide tablets campaign (with FPS Interior Affairs) Provincial medical commissions (with FPS Public Health) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI)

BAPCOC (with FPS Public Health) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Interdepartmental network on “information society services” (with FPS Economy) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI) Working group on blood of the Belgian Federal Supreme Health Council Working group on cells, tissues and organs of the Belgian Federal Supreme Health Council
BAPCOC (with FPS Public Health) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office e-MED (electronic prescription of medicines) (with FPS Public Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Guidance committee of the network of medicalpharmaceutical committees Interdepartmental committee of experts on blood, organs, cells, tissues and embryos (with FPS Public Health, KCE, RIZIV - INAMI and WIV - ISP) Interdepartmental network on “information society services” (with FPS Economy) Strategic unit/RIZIV – INAMI Unavailability of medicines (with RIZIV - INAMI) Working group on blood of the Belgian Federal Supreme Health Council Working group on cells, tissues and organs of the Belgian Federal Supreme Health Council

BAPCOC (with FPS Public Health) Board for biosafety (with WIV - ISP and the Biosafety and Biotechnology Service) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Professional Ethics Committee (with FPS Public Health - DG Animals - Plants - Foodstuffs) Strategic unit/RIZIV - INAMI
BAPCOC (with FPS Public Health) Board for biosafety (with WIV - ISP and the Biosafety and Biotechnology Service) Consultation platform with FAVV - AFSCA, FPS Public Health and Public Health Minister’s Office “Grey area” consultation platform (with FPS Public Health and FAVV - AFSCA) Professional Ethics Committee (with FPS Public Health - DG Animals - Plants - Foodstuffs) Strategic unit/RIZIV - INAMI

and Public Health Minister’s office “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS
and Public Health Minister’s office “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS Health and RIZIV - INAMI) “Grey area” consultation platform (with FPS Economie, FPS

In June 2002, concerned with the recrudescence of MRSA in Belgium, the GDEPIH-GOSPIZ and the Health Council proposed to revise the national guidelines and update the recommended policies with evidence from studies published in the last decade and dealing with the local epidemiological situation.
2 Evolution de la révision des recommandations en 2003 En juin 2002, s’inquiétant de la recrudescence de MRSA en Belgique, le GDEPIH-GOSPIZ et le Conseil supérieur d’Hygiène ont proposé de revoir les recommandations nationales et de mettre à jour les politiques conseillées à l’aide des résultats des études publiées au cours des dix dernières années, tout en se concentrant sur la situation épidémiologique locale.

With a previous attempted suicide constituting the most important risk factor for a renewed attempt and with a minority of patients seeking professional help after a first attempt (according to the WHO, only one in four is admitted to hospital), it is absolutely vital that as many health professionals as possible (doctors, specialists, pharmacists, home care nurses, etc) should receive adequate training to recognise the risks of suicide and refer the patient to the appropriate health professional.
Si une tentative de suicide antérieure est le facteur de risque le plus important pour une nouvelle tentative de suicide, et si une minorité de patients font appel à l’aide professionnelle après une première tentative (seulement 1 sur 4 est pris en charge par le milieu hospitalier selon l’OMS), c’est une condition absolue qu’un maximum de prestataires de soins (médecins, spécialistes, pharmaciens, infirmières à domicile, etc) soient formés de façon adéquate pour reconnaître les risques de suicide et pour orienter vers le prestataire de soins professionnel adéquat.

The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.
The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.

HGR 8838: Peptide Receptor Radionuclide Therapy “In this advisory report, the Superior Health Council provides a risk assessment (efficacy, toxicity, safety and radioprotection) for Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium-177 and Yttrium-90 for patients diagnosed with gastroenteropancreatic neuroendocrine tumours.
CSS 8838: Peptide Receptor Radionuclide Therapy “In this advisory report, the Superior Health Council provides a risk assessment (efficacy, toxicity, safety and radioprotection) for Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium-177 and Yttrium-90 for patients diagnosed with gastroenteropancreatic neuroendocrine tumours.

The Federal Agency for Medicines and Health Products faced numerous challenges in 2007: constructing a dynamic and efficient public service thanks to the newly acquired autonomy and transparent and professional management; developing into an institution with a national and international reputation; and becoming a learning organisation, capable of meeting people’s expectations with regard to public health.
The Federal Agency for Medicines and Health Products faced numerous challenges in 2007: constructing a dynamic and efficient public service thanks to the newly acquired autonomy and transparent and professional management; developing into an institution with a national and international reputation; and becoming a learning organisation, capable of meeting people’s expectations with regard to public health.

Consultation platform with FAVV - AFSCA, FPS Public Health e-MED (electronic prescription of medicines) (with FPS Public e-MED (electronic prescription of medicines) (with FPS Public
Consultation platform with FAVV - AFSCA, FPS Public Health e-MED (electronic prescription of medicines) (with FPS Public e-MED (electronic prescription of medicines) (with FPS Public